Final Verdict: Research Comparison Feature Tirzepatide Retatrutide Receptor Targets GLP-1, GIP GLP-1, GIP, Glucagon Half-Life ~5 Days ~6 Days Max Published Weight Loss ~21% (72w) ~24% (48w) Liver Fat Reduction Moderate/High Extreme Primary Research Focus Glycemic Control Metabolic Reset / REE Future Outlook: Post-2025 Research Landscape As we look toward 2026 and beyond, the data from the Phase 3 TRIUMPH trials will likely solidify retatrutides position in the metabolic research hierarchy
Certificate of Analysis Third-party tested Lyophilised Stability 24 months Sealed at -20C, light-protected Reconstituted Stability Up to 3 months Cold-Chain Shipping Always Dry-cold pack, Royal Mail Tracked 24 Important Notice All compounds are sold individually and do not include research supplies
When Oral Might Make Sense Some individuals have strong aversions to self-injection that no amount of education will overcome
PGC-1 is a key player in maintaining metabolic homeostasis and is closely related to mitochondrial biogenesis, oxidative phosphorylation, and mitochondrial antioxidant defense [46]
Overall, BPC-157 currently has four routes of administration available for research: Injectable Nasal spray Oral capsules Topical Continue reading to learn more about the benefits of intranasal BPC-157 use, as well as how it compares to oral and parenteral routes
CJC-1295's advantage is its enhanced stability and longer duration of action, producing more robust GH elevation with less frequent dosing
